GlassScriptPhysician profile
Helayna Evette Brown
NPI 1508284340
$20,700.84
in general payments reported to CMS, 2019-2025
40 companies · $4,423 in 2025
The $4,423 reported for 2025 was more than what 93% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,227 · 2020: $876 · 2021: $3,416 · 2022: $3,152 · 2023: $2,782 · 2024: $3,825 · 2025: $4,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $99.99 · Long Term Medical Supply Or Device Loan: $16.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,913.42 |
| Education | $99.99 |
| Long Term Medical Supply Or Device Loan | $16.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,813.97 | 2021-2025 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Alcon Vision LLC | $1,758.75 | 2019-2025 | Clareon, Hydrus Microstent, Clareon Panoptix Pro |
| Sun Pharmaceutical Industries INC. | $1,603.73 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $1,363.31 | 2024-2025 | Xdemvy |
| New World Medical,INC. | $1,229.26 | 2022-2025 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Mallinckrodt Hospital Products INC. | $1,076.17 | 2020-2025 | Acthar |
| Sight Sciences, INC. | $1,060.36 | 2020-2025 | Omni Surgical System |
| Dompe US, INC. | $1,055.06 | 2019-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $966.60 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Abbvie INC. | $859.31 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Harrow Eye, LLC | $839.26 | 2024-2025 | Iheezo, Vevye |
| Horizon Therapeutics Plc | $563.19 | 2021-2023 | Tepezza |
| Ani Pharmaceuticals, INC. | $517.01 | 2024-2025 | Purified Cortrophin Gel |
| Abbott Laboratories | $495.81 | 2019-2025 | Eterna |
| Eyevance Pharmaceuticals LLC | $488.76 | 2019-2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $427.22 | 2020-2022 | |
| Rayner Intraocular Lenses Limited | $423.92 | 2022-2024 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $421.91 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $414.88 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $387.50 | 2019-2021 | |
| Oyster Point Pharma, INC. | $359.00 | 2022-2025 | Tyrvaya, Ryzumvi |
| Biotissue Holdings INC. | $353.49 | 2019-2024 | |
| Aerie Pharmaceuticals, INC. | $282.72 | 2019-2021 | |
| Omeros Corporation | $259.92 | 2019-2021 | |
| Rxsight INC | $240.32 | 2022-2025 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Ocular Therapeutix, INC. | $213.02 | 2022-2025 | Dextenza |
| Amgen INC. | $211.21 | 2024-2025 | Tepezza |
| Carl Zeiss Meditec USA, INC. | $200.79 | 2023 | Quatera 700 |
| Shire North American Group INC | $128.74 | 2019 | |
| Spark Therapeutics, INC. | $105.68 | 2019 | |
| Genentech USA, INC. | $97.69 | 2024 | Vabysmo |
| Curonix LLC | $89.38 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Glaukos Corporation | $84.94 | 2025 | Photrexa Viscous and Photrexa, Idosetr |
| Spinal Simplicity, LLC | $77.05 | 2021 | |
| Mallinckrodt Enterprises LLC | $65.34 | 2019 | |
| Astellas Pharma US INC | $45.54 | 2023-2024 | Izervay |
| Akorn Operating Company LLC | $43.68 | 2021 | |
| Halozyme INC | $39.07 | 2025 | Hylenex Recombinant |
| Eyepoint US, INC. | $22.46 | 2019 | |
| Ucb, INC. | $14.82 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helayna Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.